Recurrent co-alteration of HDGF and SETDB1 on chromosome 1q drives cutaneous melanoma progression and poor prognosis.


Journal

Pigment cell & melanoma research
ISSN: 1755-148X
Titre abrégé: Pigment Cell Melanoma Res
Pays: England
ID NLM: 101318927

Informations de publication

Date de publication:
05 2021
Historique:
revised: 08 10 2020
received: 01 06 2020
accepted: 12 10 2020
pubmed: 17 10 2020
medline: 11 1 2022
entrez: 16 10 2020
Statut: ppublish

Résumé

A progressive increase in copy number variation (CNV) characterizes the natural history of cutaneous melanoma progression toward later disease stages, but our understanding of genetic drivers underlying chromosomal arm-level CNVs remains limited. To identify candidate progression drivers, we mined the TCGA SKCM dataset and identified HDGF as a recurrently amplified gene whose high mRNA expression correlates with poor patient survival. Using melanocyte-specific overexpression in the zebrafish BRAF

Identifiants

pubmed: 33064882
doi: 10.1111/pcmr.12937
pmc: PMC8050117
mid: NIHMS1683752
doi:

Substances chimiques

Biomarkers, Tumor 0
Intercellular Signaling Peptides and Proteins 0
hepatoma-derived growth factor 0
Histone-Lysine N-Methyltransferase EC 2.1.1.43
SETDB1 protein, human EC 2.1.1.43
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

641-647

Subventions

Organisme : NCI NIH HHS
ID : P01 CA163222
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA103846
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007627
Pays : United States

Informations de copyright

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Nature. 2020 Feb;578(7793):122-128
pubmed: 32025013
Br J Cancer. 2010 Jan 19;102(2):428-35
pubmed: 20087356
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Cancer Res. 2005 May 15;65(10):4005-11
pubmed: 15899789
Nature. 2005 Aug 4;436(7051):720-4
pubmed: 16079850
BMC Cancer. 2011 Oct 20;11:457
pubmed: 22014102
PLoS One. 2013;8(3):e59345
pubmed: 23536873
Science. 2018 Nov 30;362(6418):1055-1060
pubmed: 30385465
Nature. 2019 Nov;575(7781):210-216
pubmed: 31645765
Cancer Cell. 2009 Apr 7;15(4):294-303
pubmed: 19345328
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Nature. 2011 Mar 24;471(7339):513-7
pubmed: 21430779
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Future Oncol. 2014 Dec;10(16):2675-85
pubmed: 25236340
Curr Biol. 2005 Feb 8;15(3):249-54
pubmed: 15694309
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Dev Biol. 2019 May 15;449(2):107-114
pubmed: 29883661
Zebrafish. 2009 Dec;6(4):397-404
pubmed: 19954345
Science. 2018 Sep 7;361(6406):1033-1037
pubmed: 30190408
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Cell Stem Cell. 2008 Feb 7;2(2):183-9
pubmed: 18371439
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Dev Biol. 2010 Dec 1;348(1):34-46
pubmed: 20832394
N Engl J Med. 2015 Nov 12;373(20):1926-36
pubmed: 26559571
Cancer Res. 2002 Dec 1;62(23):6997-7000
pubmed: 12460918
Cancer Res. 2003 Oct 15;63(20):6716-25
pubmed: 14583466

Auteurs

Maurizio Fazio (M)

Stem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA, USA.

Ellen van Rooijen (E)

Stem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA, USA.

Jeffrey K Mito (JK)

Stem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

Rodsy Modhurima (R)

Stem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Erika Weiskopf (E)

Stem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Song Yang (S)

Stem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Leonard I Zon (LI)

Stem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH